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A B S T R A C T
Purpose: To investigate if phenotypic variations have prognostic implications in juvenile myoclonic
epilepsy (JME).
Methods: Sixty-ﬁve consecutive JME patients had video-EEG recording and were followed for at least
three years. Reﬂex traits were deﬁned as seizures and/or EEG discharges induction by eye-closure, photic
stimulation, language, praxis or calculation. Patients had psychiatric evaluation and answered to STAI
(State–Trait Anxiety Inventory). Seizure control was classiﬁed according to Prasad et al. (2003).24
Patients were divided into Group 1: good seizure control and Group 2: moderate or poor seizure control.
Video-EEG/EEG evaluation was repeated in 21 patients.
Results: Forty of 65 (61.5%) patients reached good seizure control, 25 (38.5%) of whom became seizure
free. Group 2 patients had longer epilepsy duration (13.9  9.0 vs. 8.7  8.2; p = 0.019); higher prevalence
of the combination of all three seizure types (72.0% vs. 30.0%; p = 0.003); discharges in baseline EEG (56.0% vs.
22.5%; p = 0.008); seizure recording (68% vs. 20%; p < 0.001) and sensitivity to praxis (63.6% vs. 29.6%;
p = 0.023). Compared to seizure-free patients, those with persistent seizures presented younger age at
epilepsy onset (12.6  3.33 years vs. 15.4  5.47 years; p = 0.015); higher prevalence of personality disorders
(25% vs. 4%; p = 0.029); higher scores in STAI-T (45.9  11.31 vs. 36.6  11.43; p = 0.011) and higher incidence
of sensitivity to praxis (58.6% vs. 25.0%; p = 0.04) and to language (53.8 vs. 16.7%; p = 0.026) tasks. Repetition
of EEG/video-EEG revealed a parallel evolution of reﬂex traits disappearance and seizure control.
Discussion: Clinical features and reﬂex traits have prognosis implications in JME.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Juvenile myoclonic epilepsy (JME) is the most common
idiopathic generalized epilepsy (IGE) in adults, comprising up to
10% of all epilepsy patients and up to 26% of IGE.1 It is characterized
by myoclonic jerks in all cases, generalized tonic–clonic seizures
(GTCS) in about 90% and absences in one third of these individuals.2
Seizures usually begin between 12 and 18 years of age and
important clues to diagnosis include the inﬂuence of precipitant
factors traditionally represented by sleep deprivation, stress,
menstruation, fatigue, and alcohol consumption.2 Besides these
factors, seizures in JME can be triggered by cortical stimuli which
can be simple as intermittent photic stimulation (IPS)3 and eye
closure4 or complex as superior cortical functions. Among the
latter we can distinguish language tasks as reading and speaking5
and activities such as calculation, writing, playing cards or chess,
construction or drawing, which involve decision-making, complex* Corresponding author at: Rua Botucatu, 740 Vila Clementino, Sa˜o Paulo 04023-
900, SP, Brazil. Tel.: +55 11 5576 4136; fax: +55 11 5549 3819.
E-mail address: mibit@ig.com.br (Mirian S.B. Guaranha).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.10.004spatial manipulation and response by the use of a part of the body,
deﬁned as praxis-induction.6,7
JME has been considered as generally responsive to adequate
treatment, presenting rates of pharmacoresistance of around 10–
20%.8–10 Some data open questions regarding its benign nature
reporting seizure relapse in up to 70% of patients after at least one
year of seizure control.11 In a more recent population based cohort
of 23 patients with a very long follow-up of 25 years, 11 (47.8%)
were out of medication at the end, in spite of the fact that three
continue presenting myoclonia and two, rare seizures. The rate of
seizure freedom for all seizure types in this series was of only 17%.
Yet 74% of the patients had at least one major unfavorable social
outcome as failure to complete high school, unplanned pregnancy,
depression, unemployment or living alone.12
Until now, there are insufﬁcient data to allow identiﬁcation of
the factors indicating long-term prognosis in JME. Among the
potential prognostic factors, non-classical clinical presentations, as
childhood absence epilepsy evolving to JME,13 focal EEG abnor-
malities14–16 and psychiatric comorbidities, more commonly
represented by anxiety, mood and cluster B personality dis-
orders,9,17 have been recognized as factors related to difﬁculty in
achieving seizure control.vier Ltd. All rights reserved.
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patients with reﬂex traits related to higher cortical functions as
language and praxis has increasingly been recognized since early
90s,14 its importance on prognosis has only been reported in two
series of patients and a few case reports.6,14,18,19
The purpose of this study was to investigate the inﬂuence
of each feature mentioned above on response to treatment in
a prospective series of JME patients with long-term follow-up.
As it done in a tertiary center the main objective was not
to evaluate the incidence of pharmacoresistance but to
evaluate the differences among responders and difﬁcult to treat
patients.
2. Methods
2.1. Clinical evaluation
All patients were followed up in the outpatient clinic of a
tertiary center (Epilepsy Section, Department of Neurology and
Neurosurgery, Universidade Federal de Sa˜o Paulo, Sa˜o Paulo,
Brazil). Inclusion criteria were: (a) unequivocal diagnosis of JME
based on criteria deﬁned in the revised Classiﬁcation of Epilepsies
and Epileptic Syndromes20; (b) age over 12 years; (c) no evidence
of neurological or intellectual deﬁcits and (d) more than 4 years of
formal education.
Since different electroclinical subtypes of JME might inﬂuence
prognosis, patients were subdivided in four groups: classic JME,
childhood absence epilepsy persisting and evolving into JME, JME
with adolescent onset pyknoleptic absence and JME with astatic
seizures.13
Patients also had psychiatric interviews as part of their clinical
characterization by the same psychiatrist (G.M.A.F.) using two
structured questionnaires: the Schedule Clinical Interview for
DSM-IV, Axis I (SCID-I) and Axis II (SCID-II), consisting in
psychiatric scales based on DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, third edition, revised). Axis I refers to
the evaluation of most psychiatric diseases (e.g. mood, anxiety and
psychotic disorders), while Axis II refers to the evaluation of all
types of personality disorders. For those younger than 18 the
Brazilian version of the Schedule for Affective Disorders and
Schizophrenia for School-Aged Children (K-SADS-PL) was applied.
State–Trait Anxiety Inventory (STAI), composed of two scales
intended to measure state (STAI-S) and trait (STAI-T) anxiety
components was used in order to measure anxiety severity.21
2.2. Video-EEG
Consecutive patients who met clinical and EEG criteria for JME
diagnosis were submitted to a video-EEG monitoring for a 4–6 h
period, comprehending a research protocol approved by the Ethics
Committee of Universidade Federal de Sa˜o Paulo, after informed
consent was obtained from all participants. Clinical signs of
antiepileptic drug (AED) intoxication, occurrence of a GTCS and use
of intravenous AED within the last 72 h were exclusion criteria as
well as great difﬁculty in performing any task independent of
schooling.
Video-EEG was recorded on a 32-channel digital equipment
(Biologic1, software Ceegraph1) using the 10–20 International
Electrode System, in addition to perioral and deltoid electrodes.
Medications were maintained in all treated patients. After having
slept for at least 6 h, all patients had 30 min of awake EEG
recording starting at 7 a.m. After this baseline record, patients
performed habitual methods of activation as eye-closure, hyper-
ventilation, IPS, sleep and neuropsychological tasks represented by
reading silently and aloud, talking, writing, mental and written
calculations, drawing and spatial construction puzzles. Theprotocol and its analysis were based on those reported by
Matsuoka et al.7 and Mayer.22
Reﬂex traits were characterized by seizure induction and/or
EEG discharges increasing by activationmethods in video-EEG and
are described elsewhere.23
EEG tracings were also analyzed regarding the presence of focal
abnormalities such as focal slow-wave bursts and focal epileptic
discharges; amplitude asymmetry (50%) of generalized dis-
charges; asymmetry of response to IPS and focal onset of
generalized discharges.16 Bilateral anterior or posterior discharges
were not considered focal abnormalities.
After a period of 2–6 years (mean 4.4), 16 patients who had
presented reﬂex traits in the ﬁrst evaluation had a second video-
EEG recording and ﬁve, who had not expressed neuropsychological
induced traits had data obtained from routine EEG with eye-
closure and IPS.
2.3. Follow-up
The various seizure types, possible seizure triggers, AED therapy,
treatment adherence and adverse effects were observed as well as
routine blood tests, AED level determination, and routine EEGs.
Fifty-eight patients were on AEDs when enrolled in the study.
Patients were treated by adjustment in lifestyle being oriented
to avoid precipitant factors as sleep deprivation and alcohol
consumption. They received sodium valproate (VPA), as the ﬁrst
choice drug, in mono or polytherapy and other AED considered
reasonably effective in IGE and JME treatment such as topiramate
(TPM), lamotrigine (LTG), phenobarbital (PB) and benzodiazepines.
Doses and AEDs were chosen according to clinical response and
adverse effects.
Estimation of the frequency of seizures was based on the review
of seizure calendars and speciﬁc questioning of the patient and
family members. Evaluation of seizure control was done according
to Prasad et al. [24], as follows: GTCS, good (<1 seizure per year),
moderate (1–4 seizures per year), or poor (>4 seizures per year);
myoclonia, good (<5 single seizures or clusters per month, rare
seizures, or occasional seizures), moderate (5–14 single seizures or
clusters per month, several seizures, or frequent seizures), or poor
(15 single seizures or clusters per month or daily seizures); and
absence, good (<5 seizures per month, rare seizures, or occasional
seizures), moderate (5–14 seizures per month, several seizures, or
frequent seizures), or poor (15 seizures per month, frequent
seizures, or daily seizures).
In a ﬁrst analysis patients were followed for at least three years
and classiﬁed into two groups, Group 1: good seizure control for all
seizure types in the last two years and Group 2: moderate or poor
seizure control. Seizure-free patients were included in the good
seizure control group. Since the main goal of epilepsy treatment is
to get patients seizure-free, in a second analysis we compared
those completely seizure-free for at least the last two years to
those with any degree of persistence of seizures.
Statistical analysis was performed using computer softwares
SPSS for Windows release 10.0.1 standard version; STATISTICA
version 7, StatSoft, Inc and STATA 8, Data Analysis and Statistical
Software, Stata Corporation. Fisher’s exact test for categorical and
Student’s t-test for continuous variables were applied for group
comparisons. A p value of <0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Clinical features
Among 76 enrolled patients we kept following 65 (85.5%). Six
lost follow-up, two had non adherence to treatment, one had
Table 1
Demographic and clinical data.
JME (n=65)
Gender male 32 (49.2%)
Age (years) 24.407.28
Manual dominance right handed 58 (89.2%)
Age at epilepsy onset (years) 13.704.48
Duration of epilepsy (years) 10.738.73
Seizure types
Myoclonia 65 (100.0%)
Generalized tonic–clonic 62 (95.3%)
Absences 31 (47.7%)
Family history 46 (70.8%)
JME subtype
Classic 48 (73.85%)
CAE evolving to JME 7 (10.77%)
With adolescent onset absence 10 (15.38%)
With astatic seizures 0 (0.0%)
Psychiatric disorders 31 (47.6%)
Personality disorders 11 (16.9%)
Generalized anxiety disorder 11 (16.9%)
Mood disorder (depression) 8 (12.3%)
Schizophrenia 1 (1.5%)
JME: juvenile myoclonic epilepsy; CAE: childhood absence epilepsy.
Table 2
Prognosis related to clinical features.
Group 1
(n=40)
Group 2
(n=25)
p-Value
Epilepsy duration (years) 8.78.20 13.99.0 0.019
Seizure types
Myoclonia 2 (5.0%) 0
Myoclonia +GTCS 25 (62.5%) 7 (28.0%)
Myoclonia +GTCS+absences 12 (30.0%) 18 (72.0%) 0.003
Myoclonia + absences 1 (2.5%) 0
JME subtypes
Classic JME 33 (82.5%) 15 (60.0%)
CAE/JME 4 (10.0%) 3 (12.0%)
JME with adolescent onset
pyknoleptic absence
3 (7.5%) 7 (28.0%) 0.067
JME: juvenilemyoclonic epilepsy; CAE/JME: childhood absence epilepsy evolving to
juvenile myoclonic epilepsy; GTCS: generalized tonic–clonic seizures; STAI: State–
Trait Anxiety Inventory.
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than epilepsy. One patient without seizure control had sudden
unexpected death after a follow-up period of seven years and his
data were considered for analysis. Demographic and clinical data
are presented in Table 1.
Patients had a follow-up of 5.72  1.91 years. Control of each
seizure type was veriﬁed as follows: myoclonia – good 53/65 (81.5%),
moderate 4/65 (6.2%) and poor 8/65 (12.3%); GTCS – good 44/62
(71%), moderate 9/62 (14.5%) and poor 9/62 (14.5%); absences – good
21/31 (67.7%), moderate 4/31(12.9%) and poor 6/31 (19.4%).
Forty of 65 (61.5%) patients reached good seizure control for all
seizure types (Group 1), 25 (38.5%) of whom became completely
seizure free. Twenty-ﬁve patients (38.5%), nine with moderate and
16 with poor seizure control constituted Group 2.
At the end of the study, four patients (6.2%) were seizure free
and out of medications. The most common AED was VPA in 49/61
(80.3%), followed by TPM in 17 (27.9%), clonazepam (CZP) in 11
(18.0%), LTG in six (9.2%), PB in six (9.2%), clobazam in four (6.2%)
and carbamazepine in two (3.1%). Thirty-eight of 61 (62.3%)
medicated patients were on monotherapy: 31 (81.6%) on VPA, six
(15.8%) on TPM and one (2.6%) on CZP.
Among 49 patients in use of VPA, 30 (61.2%)were in Group 1; 17
(34.7%) of them became seizure-free. Group 1 also included seven
of 17 patients (41.1%) taking TPM, three (17.6%) of whom seizure-Table 3
Prognosis related to clinical features in seizure-free opposed to those with persistent s
Seizure-free patients
(n=25)
Age at epilepsy onset (years) 15.45.47
Personality disorders 1 (4%)
Anxiety disorders Seizure-free patients
(n=16)
STAI (STATE) score 37.312.0
Slight degree 12 (75%)
Moderate to severe degree 4 (25.0%)
STAI (TRACE) score 36.611.4
Slight degree 14 (87.5%)
Moderate to severe degree 2 (12.5%)
STAI: State–Trait Anxiety Inventory.free. Five of six patients in use of PBwere in Group 2 (p = 0.038) and
had persistence of GTCS (p = 0.041). Five of six patients in use of
LTG (p = 0.038) and 10 of 15 on benzodiazepines (p = 0.033) were
also in Group 2. All nine patients on three or more AEDs belonged
to the latter group (p < 0.001). Group 2 patients were in use of
higher doses of VPA (1450  879.24 mg vs. 811.7  375.01 mg,
p = 0.001) and of CZP (2.33  1.03 vs. 0.80  0.69, p = 0.02); there was
a higher number of Group 2 patients taking 2000–3500 mg of VPA
daily (p = 0.028).
The analysis of clinical data revealed no differences between the
two groups in relation to gender distribution (Group 1: 52.5%male
vs. Group 2: 44%), family history of epilepsy (Group 1: 75% vs.
Group 2: 64%) or follow-up duration (Group 1: 5.9  1.93 vs. Group
2: 5.4  1.87).
Table 2 shows correlation between clinical data and distribu-
tion of patients according to seizure control. Comparing to Group 1,
patients in Group 2 had higher epilepsy duration and incidence of
combination of all three seizure types, myoclonia, absences and
GTCS. Regarding JME subtypes, Group 2 had a marginally
signiﬁcant higher representation of JME with adolescent onset
pyknoleptic absence than the good seizure control group.
When we compared the 25 patients who became completely
seizure-free with those with any degree of persistent seizures
(Table 3), the latter presented earlier onset of epilepsy and higher
incidence of cluster B personality disorders. While 87.5% of
seizure-free patients had STAI slight degrees of anxiety traits,
68.8% of patients with persistent seizures had moderate to severe
degrees of anxiety traits. In addition, patients with persistent
seizures had signiﬁcantly higher scores in anxiety-trait and
marginally signiﬁcant higher scores in anxiety-state subscale.eizures.
Patients with persistent seizures
(n=40)
p-Value
12.63.33 0.015
10 (25%) 0.029
Patients with persistent seizures
(n=32)
p-Value
44.110.8 0.054
14 (43.8%) 0.065
18 (56.2%)
45.911.3 0.011
10 (31.3%) 0.001
22 (68.8%)
[()TD$FIG]
Fig. 2. Prognosis for patients with reﬂex traits expressed as induced seizures. IPS:
intermittent photic stimulation. *p = 0.025; **p = 0.05; ***p = 0.004.
[()TD$FIG]
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duration (14.6  8.35 vs. 8.9  9.08, p = 0.028) and earlier onset of
epilepsy (12.1  3.05 vs. 15.4  5.47, p = 0.012) than seizure-free
patients.
3.2. Video-EEG
A higher number of patients with persistent seizures had
epileptic discharges in baseline video-EEG (47.5% vs. 16%,
p = 0.016) and also seizures recorded (55% vs. 12%, p = 0.001) in
comparison with seizure-free patients.
3.3. Focal EEG abnormalities
Eleven patients had normal tracings. Among the remaining 54
patients, 27 (50%) had focal EEG abnormalities. Twenty-two had
50% amplitude asymmetry of generalized discharges; 15 focal
epileptiform discharges; four slow wave bursts; three focal onset
of generalized discharges and two asymmetry of photoparoxysmal
response. Among 17 patients whose EEG presented focal dis-
charges or slow wave bursts, 10 had frontal localization, three
parietal, three temporal and one, occipital.
Among 54 patients with epileptiform discharges, focal abnor-
malities were seen in 7/16 (43.8%) who became seizure-free and in
20 of 38 (52.6%) who had persistent seizures (p = 0.76).
3.4. Reﬂex traits
Fifteen of 27 (55.6%) patients with none or only general
precipitants were seizure-free. For those with other modalities of
precipitant factors the rate of seizure freedom dropped to 4/13
(30.8%) for eye-closure, 4/16 (25%) for photic, 5/17 (29.4%) for
language and 5/22 (22.7%) for praxis sensitive patients.
Fig. 1 depicts prognosis related to reﬂex traits. In comparison to
seizure-free, those with persistent seizures had a higher propor-
tion of praxis (58.6% vs. 25%, p = 0.04) and language sensitivity
(53.8% vs. 16.7%, p = 0.026). Photosensitivity was only marginally
related to persistent seizures (50% vs. 21.1% in seizure-free
patients, p = 0.064). Written calculation was considered among
praxical activities. Mental calculation activated epileptic dis-
charges in only four patients, none of them reached seizure
freedom (Fig. 1). The prognosis related to seizures induction is in
Fig. 2. All of the ﬁve patients with seizures triggered by IPS were
not seizure-free (18.5% vs. 0.0%, p = 0.05); the same occurred with
six patients with eye closure induced seizures (21.4% vs. 0.0%,
p = 0.025). Also, praxis-induced seizures prevailed among non
[()TD$FIG]
Fig. 1. Prognosis for patients with reﬂex traits expressed as EEG discharges and/or
seizures induction. *p = 0.04; **p = 0.026.seizure-free patients (35.3% vs. 4%, p = 0.004). There was no patient
exhibiting seizures induced by mental calculation (Fig. 2).
Among 38 patients who had presented at least one reﬂex trait,
21 performed a second evaluation by EEG/video-EEG. The relation
of reﬂex traits evolution and seizure control is represented in Fig. 3.
Notice that most patients of Group 1 evolved with traits
disappearance while most of those in Group 2 had traits
persistence.
4. Discussion
In this prospective study we investigated the response to
treatment in 65 patients with JME with three years of follow-up
utilizing the seizure freedom criteria of Janz,25 deﬁned as a
remission for at least two years. In Janz series of 49 JME patients,
25% did not become seizure free and 91% had seizure relapses after
medication reduction or suspension.25 Another study revealed
unsatisfactory response to treatment in only four of 43 (9%)
patients.26 A prospective study with a follow-up of >3 years
reported that 6/50 (12%) patients continued to have seizures.8
Recent studies have demonstrated variable rates of JME pharma-
coresistance; in a population-based series of 13%12 and in
outpatient clinics of 15.5%9 and 30%.15 Responsiveness toFig. 3. Re-evaluation by EEG/video-EEG.
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completely seizure-free patients and those with persistence of
occasional myoclonia or ‘‘rare’’ seizures, including GTCS or
excluding this seizure type. Classiﬁcation of patients regarding
seizure control is not so clear when dealing with patients having
some persistent seizures or relapsing ones. In this way, one study
revealed persistence of GTCS in 18.6%, but that of other seizure
types was not clearly quantiﬁed.27 However, most of studies were
retrospective, based on questionnaires or medical records review
analyzing variable periods of follow-up from one to three or more
years. Pseudo-resistance represented by the lack of compliance,
insufﬁcient treatment and abnormal lifestyle is another important
factor in JME treatment, contributing to 9.7% of persisting
seizures.9 Finally, the population studiedwas quite heterogeneous,
varying from community-based to tertiary centers. It is believed
that a higher proportion of refractory JME has been reported by
specialized clinics probably due to the fact that difﬁcult to treat
patients are preferentially referred to such centers.28 A more
reliable evaluation of these patients in such institutions could also
contribute to these results.
In our study performed in a tertiary university center we kept
following 65 out of 76 (85.5%) patients for at least three years. The
criteria for response to treatmentwere established for each seizure
type and it was cautioned to exclude pseudo-refractory epilepsy
patients. We found 25 out of 65 (38.5%) patients with moderate
and poor seizure control. Up to now, the highest reported rate in
patients followed for three years had been 45% for GTCS.14 Both
samples might have been biased with representation of more
severe epilepsy.
Despite the fact that there are no class I studies to guide initial
therapy of JME,29 according to SANAD, a large randomized,
prospective trial, reporting on 119 patients with JME, VPA should
remain as drug of choice for the majority of generalized and non-
classiﬁed epilepsies, as it was more effective than LTG and better
tolerated than TPMwith the possible exception of childbearing age
women.30 Open-label studies using VPA in JME showed a 41–88%
seizure-free rate for patients receiving this AED as monotherapy or
add-on.9,31 In Nicolson et al. series,32 54.3% of 962 IGE patients
achieved one year period of remission; this was most likely with
VPA monotherapy (52.1%), with lower rates for LTG and TPM
(16.7% and 34.6%, respectively). Although the number of patients
treated in our series was much smaller, we found seizure freedom
outcome as 34.7% for VPA followed by 17.6% for TPM and 14.3% for
LTG. Our data regarding response to speciﬁc AED suggest low
efﬁcacy of PB and LTG in JME since from the six patients receiving
PB, only one became seizure-free, the same occurring to the six
patients receiving LTG.
The present study did not have as itsmain target to estimate the
rate of non-responders but to look for features that could
differentiate the group with refractory or more difﬁcult to control
epilepsy.
In this series, seizure persistencewas related to higher duration
of epilepsy, similar to other reports.14,33 Otherwise, patients who
did not became seizure-free had a lower age at epilepsy onset.
Earlier onset of epilepsy was also emphasized in the resistant form
of childhood absence epilepsy and might be an expression of
different genetic basis.34
Regarding seizure types, myoclonic seizures alone, in combi-
nation to GTCS on awakening or to absences were related to a
better prognosis when compared to the combination of all the
three seizure types in the same patient,9,10,14 a fact also observed in
the present series.
Different subtypes of JME patients deﬁned by clinical and EEG
criteria had no difference regarding seizure control and it was
observed only a tendency toward a worse seizure control in the
group with adolescent onset pyknoleptic absence. This is differentfrom the original description, in which this subtype accounted for
similar non-responsive rates as classical subtype (44 and 42%,
respectively) while childhood absence epilepsy evolving to JME
(subtype 2) had 91.4% of patients not seizure-free.13
Regarding psychiatric disorders, previous reports of higher
frequency of personality disorders and generalized anxiety
disorder in patients with drug resistance9,17 were conﬁrmed in
this study. Higher degrees of anxiety measured by trace STAI scale
were found among no seizure-free patients. Psychiatric disorders
might share pathophysiological mechanisms with JME, both
related to dysfunction in fronto-thalamic circuitry or the
psychiatric disturbance per se might have a negative impact over
epilepsy treatment response. In fact, current evidence exists of
more severe abnormalities demonstrated by spectroscopy and
voxel-based volumetry in thalamic regions and frontal lobes, in
JME patients with psychiatric disorders compared to thosewithout
such ﬁnding.35,36
As to EEG features, among the characteristics associated to
persistence of seizures, presence of epileptic discharges in baseline
and seizure registration might suggest these patients had a higher
epilepsy severity since the beginning of the follow-up period.
The articles dealing with focal EEG abnormalities in JME do
considerations concerning the difﬁculties they add to diagnosis and
advocate controversial implications of this feature in prognosis.
While some authors37,38 described no correlation between focal
abnormalities and response to treatment, others emphasized they
should not be misinterpreted as indicative of focal epilepsies, a
common mistake in JME, and its importance as a sign of worse
prognosis.15,16 Our analysis on the presence of focal EEG abnormali-
ties did not reveal a signiﬁcant difference regarding seizure control,
although some possible associations might be suggested. In this
manner, twoof threepatientswithparietal and sixof 10with frontal
abnormalities had praxis induction. In praxis sensitivity, the most
affected region may be in either the frontal or the parietal lobes, as
suggested by Goossens et al.39 The patient with occipital abnormal-
ities was photosensitive and all of three with temporal abnormali-
tieshadpsychiatricdisorders, twowithgeneralizedanxietydisorder
and one, cluster B personality disorder.
Reﬂex traits might have implication on prognosis. Matsuoka14
for the ﬁrst time reported the negative impact of neuropsycholog-
ical activation on prognosis of JME. Inoue and Kubota6 analyzing a
series of 134 JME patients reported that seizure-freedom for more
than three years dropped from 53/77 (69%) in patients with none
or only general precipitants, to 18/32 (56%) in photosensitive and
12/25 (48%) for praxis sensitive patients. This, therefore, suggested
that the presence of reﬂex traits could represent an aggravating
feature in JME. In this sense, our study showed that the rate of
seizure freedom dropped from 15/27 (55.6%) in patients with none
or general precipitant factors to 4/16 (25%) in photosensitive and to
5/22 (22.7%) for praxis sensitive patients, the latter reaching
statistical signiﬁcance level.
Approximately 30% of JME patients have a photoparoxysmal
EEG response, although most articles do not refer to prognostic
signiﬁcance of this trait in JME.40 A very good response to VPA has
been reported among photosensitive patients, especially in pure
photosensitive epilepsy and in JME,38,40,41 although no single – or
double-blind trials to evaluate treatments in visually induced
seizures have been performed and even VPA, the drug of choice has
never been investigated as such.42 In our series eye-closure and
photosensitivity were related to a worse prognosis when inducing
clinical seizures. Additionally while only one out of the six Group 1
patients continued expressing the trait, all in Group 2 were still
photosensitive at the end of the study. Another series examined 50
patients with photosensitive epilepsies and found that abnormali-
ties in IPS occurred in 76% of patients with recent seizures vs. in
33% of seizure-free patients for more than one year.43
M.S.B. Guaranha et al. / Seizure 20 (2011) 42–48 47Similarly, in the present study language sensitivity had a
negative impact on prognosis. Although reading epilepsy has been
described as having a good prognosis,44,45 this might not be true in
language-induced seizures in JME. In this respect, among nine
patients in Mayer et al. series,5 three were not seizure-free on VPA
as 14/17 (82.3%) of language sensitive patients in ours.
Calculation activated epileptiform discharges in four patients
and at the end all were not seizure-free. Seizures induced by
calculation using a ‘‘soroban’’ (Japanese abacus), could not be
induced by mental calculation.46 The latter would exert a higher
provocative effect when associated to praxis as in the use of
soroban or written calculation. In fact, for the majority of JME
patients, mental calculation might have an inhibitory effect
presumably by the activation of circuitries that inhibits activity
in the motor frontal area more related to ictogenesis.23
Reﬂex traits evolution over time was described in a study on
two JME patients evaluated for more than 20 years whose
susceptibility to seizures during performance of praxis tasks
lasted all period, although the effect decreased with age.19 The
repeated exams in our study suggested a parallel evolution of
seizure control and reﬂex traits expression, with persistent traits in
the majority of Group 2 patients and disappearance in most of
Group 1.
Data on reﬂex traits indicate they are expression of hyperex-
citability in JME patients. The most recent theory on IGE
mechanisms attributes a fundamental role of cortex in initiating
spike and wave discharges.47 Hyperexcitability in JME probably is
not homogeneous in the entire cortex and reﬂex traits might be the
expression of higher excitability in speciﬁc cortical regions.
5. Conclusions
Clinical features including reﬂex traits have prognosis implica-
tions in JME. Longer epilepsy duration, combination of all three
seizure types, discharges in baseline video-EEG, seizures recording
and praxis sensitivity were negative prognostic factors for seizure
control. Additionally, a lower rate of seizure freedom was
associated to earlier age at epilepsy onset, personality disorders,
anxiety, sensitivity to praxis or to language tasks and seizure
induction by eye-closure or IPS. Reﬂex traits disappearance was
generally accompanied by seizure control. All these endopheno-
types might serve as prognosis signaling in JME.
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